Warning: The NCBI web site requires JavaScript to function. more...
An official website of the United States government
The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.
CDKL5 DiscoveRx kinase panel
Assay data:1 Tested
SummaryRelated BioAssays by Target
KinomeScan assay: inhibition of CDKL5
Assay data:108 Tested
CDKL5 Invitrogen Lab (UK) kinase screen (BI)
Inhibition of wild-type human partial length CDKL5 (M1 to S337 residues) expressed in mammalian expression system assessed as residual binding level at 1 uM by Kinomescan method relative to control
SummaryPubMed CitationRelated BioAssays by Target
Inhibition of human recombinant CDKL5 in presence of ATP by Z-lyte kinase assay
Inhibition of human CDKL5 assessed as percent of control at 2000 nM by KINOMEscan assay relative to control
Inhibition of CDKL5 (unknown origin) at 10 uM relative to control
Assay data:3 Tested
Inhibition of DNA-tagged human CDKL5 assessed as percent of control at 50000 nM by qPCR analysis relative to control
Inhibition of human CDKL5 assessed as percent of control at 1000 nM by KINOMEscan assay relative to control
Inhibition of human partial length CDKL5 (M1 to S337 residues) expressed in mammalian expression system assessed as residual activity at 10 uM by kinome scan method relative to control
Binding affinity to wild-type human partial length CDKL5 (M1 to S337 residues) expressed in mammalian expression system assessed as residual binding level at 10 uM by Kinomescan method relative to control
Inhibition of wild-type human partial length CDKL5 (M1 to S337 residues) expressed in mammalian expression system at 1 uM by Kinomescan method relative to control
Inhibition of wild-type human partial length CDKL5 (M1 to S337 residues) expressed in mammalian expression system at 10 uM by Kinomescan method relative to control
Binding affinity to wild-type human partial length CDKL5 (M1 to S337 residues) expressed in mammalian expression system assessed as residual binding level at 1 uM by Kinomescan method relative to control
Inhibition of wild-type human partial length CDKL5 (M1 to S337 residues) expressed in mammalian expression system assessed as residual activity at 10 uM by Kinomescan method relative to control
RNAi screen for vemurafenib enhancer genes in BRAFV600 melanoma - Primary Screen
Assay data:790 Active, 18119 Tested
Summary
Filters: Manage Filters
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on